menu
    • menu
    [{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMB-150","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Imbrium Therapeutics

    Menu

    Imbrium Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Urology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imbrium Completes Clinical Trial of Treatment for Interstitial Cystitis/BPS

                            Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of overactive bladder syndrome.

                            Product Name : IMB-115

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Urology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imbrium Therapeutics Announces Results from Phase 1b Study in OAB Syndrome

                            Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of overactive bladder syndrome.

                            Product Name : IMB-115

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imbrium Submits IND Application to Evaluate Sunobinop for Alcohol Use Disorder

                            Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of moderate to severe alcohol use disorder.

                            Product Name : IMB-115

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 08, 2024

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMB-150

                            Therapeutic Area : Urology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cy...

                            Details : IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.

                            Product Name : LYT-503

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 20, 2022

                            Lead Product(s) : IMB-150

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Imbrium Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115

                            Details : IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor i...

                            Product Name : IMB-115

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 28, 2020

                            Lead Product(s) : Sunobinop

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth